Patent ID: 11939319
Assignee: UCB PHARMA GMBH
Field: Organic fine chemistry (Chemistry)
Classification: CPC C  A | IPC C

Claim 19:
20. A method of treating a demyelination disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1, wherein the demyelination disorder is
multiple sclerosis (MS);
neuromyelitis optica;
chronic relapsing inflammatory optic neuritis;
acute disseminated encephalomyelitis,
acute haemorrhagic leukoencephalitis (HAL);
periventricular leukomalacia;
demyelination due to viral infections;
central pontine and extrapontine myelinolysis;
demyelination due to traumatic brain tissue damage;
demyelination in response to hypoxia, stroke or ischaemia or other cardiovascular diseases;
demyelination due to exposure to carbon dioxide, cyanide, or other CNS toxins;
Schilder's disease;
Balo concentric sclerosis;
Perinatal encephalopathy;
Amyotrophic lateral sclerosis (ALS);
Alzheimer's disease (AD);
Multiple system atrophy;
Parkinson's Disease;
Spinocerebellar ataxia (SCA);
Schizophrenia;
leukodystrophies, peripheral demyelinating neuropathies; Dejerine-Sottas syndrome; or
Charcot-Marie-Tooth disease.